Cargando…

Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells

Malignant glial tumors (gliomas) are the second (after cerebral stroke) cause of death from diseases of the central nervous system. The current routine therapy, involving a combination of tumor resection, radio-, and chemo-therapy, only modestly improves survival. Sonodynamic therapy (SDT) has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilmin, Krzysztof, Kujawska, Tamara, Grieb, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912826/
https://www.ncbi.nlm.nih.gov/pubmed/31766152
http://dx.doi.org/10.3390/cells8111428
_version_ 1783479551132696576
author Bilmin, Krzysztof
Kujawska, Tamara
Grieb, Paweł
author_facet Bilmin, Krzysztof
Kujawska, Tamara
Grieb, Paweł
author_sort Bilmin, Krzysztof
collection PubMed
description Malignant glial tumors (gliomas) are the second (after cerebral stroke) cause of death from diseases of the central nervous system. The current routine therapy, involving a combination of tumor resection, radio-, and chemo-therapy, only modestly improves survival. Sonodynamic therapy (SDT) has been broadly defined as a synergistic effect of sonication applied in combination with substances referred to as “sonosensitizers”. The current review focuses on the possibility of the use of tumor-seeking sonosensitizers, in particular 5-aminolevulinic acid, to control recurring gliomas. In this application, SDT employs a principle similar to that of the more widely-known photodynamic therapy of superficially located cancers, the difference being the use of ultrasound instead of light to deliver the energy necessary to eliminate the sensitized malignant cells. The ability of ultrasound to penetrate brain tissues makes it possible to reach deeply localized intracranial tumors such as gliomas. The major potential advantage of this variant of SDT is its relative non-invasiveness and possibility of repeated application. Until now, there have been no clinical data regarding the efficacy and safety of such treatment for malignant gliomas, but the preclinical data are encouraging.
format Online
Article
Text
id pubmed-6912826
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69128262020-01-02 Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells Bilmin, Krzysztof Kujawska, Tamara Grieb, Paweł Cells Review Malignant glial tumors (gliomas) are the second (after cerebral stroke) cause of death from diseases of the central nervous system. The current routine therapy, involving a combination of tumor resection, radio-, and chemo-therapy, only modestly improves survival. Sonodynamic therapy (SDT) has been broadly defined as a synergistic effect of sonication applied in combination with substances referred to as “sonosensitizers”. The current review focuses on the possibility of the use of tumor-seeking sonosensitizers, in particular 5-aminolevulinic acid, to control recurring gliomas. In this application, SDT employs a principle similar to that of the more widely-known photodynamic therapy of superficially located cancers, the difference being the use of ultrasound instead of light to deliver the energy necessary to eliminate the sensitized malignant cells. The ability of ultrasound to penetrate brain tissues makes it possible to reach deeply localized intracranial tumors such as gliomas. The major potential advantage of this variant of SDT is its relative non-invasiveness and possibility of repeated application. Until now, there have been no clinical data regarding the efficacy and safety of such treatment for malignant gliomas, but the preclinical data are encouraging. MDPI 2019-11-13 /pmc/articles/PMC6912826/ /pubmed/31766152 http://dx.doi.org/10.3390/cells8111428 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bilmin, Krzysztof
Kujawska, Tamara
Grieb, Paweł
Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells
title Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells
title_full Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells
title_fullStr Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells
title_full_unstemmed Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells
title_short Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells
title_sort sonodynamic therapy for gliomas. perspectives and prospects of selective sonosensitization of glioma cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912826/
https://www.ncbi.nlm.nih.gov/pubmed/31766152
http://dx.doi.org/10.3390/cells8111428
work_keys_str_mv AT bilminkrzysztof sonodynamictherapyforgliomasperspectivesandprospectsofselectivesonosensitizationofgliomacells
AT kujawskatamara sonodynamictherapyforgliomasperspectivesandprospectsofselectivesonosensitizationofgliomacells
AT griebpaweł sonodynamictherapyforgliomasperspectivesandprospectsofselectivesonosensitizationofgliomacells